170 related articles for article (PubMed ID: 30341677)
1. Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development.
Abramova N; Hubbard J; Schertz J; Richter E
Drug Saf; 2019 Mar; 42(3):453-461. PubMed ID: 30341677
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
3. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
[TBL] [Abstract][Full Text] [Related]
5. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment.
Agostinetto R
Reprod Biol Endocrinol; 2009 May; 7():48. PubMed ID: 19450267
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies.
Picard M; Rossier C; Papasouliotis O; Lugan I
Curr Med Res Opin; 2008 Apr; 24(4):1199-208. PubMed ID: 18348746
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
[TBL] [Abstract][Full Text] [Related]
10. Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.
Martini AE; Beall S; Ball GD; Hayward B; D'Hooghe T; Mahony MC; Collares F; Catherino AB
Front Endocrinol (Lausanne); 2023; 14():1195632. PubMed ID: 37727455
[TBL] [Abstract][Full Text] [Related]
11. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
13. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
Humaidan P; Schertz J; Fischer R
BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102350. PubMed ID: 37320996
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.
Marrs R; Meldrum D; Muasher S; Schoolcraft W; Werlin L; Kelly E
Reprod Biomed Online; 2004 Feb; 8(2):175-82. PubMed ID: 14989794
[TBL] [Abstract][Full Text] [Related]
19. Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.
Koloda Y; Korsak V; Rozenson O; Anshina M; Sagamonova K; Baranov I; Yakovenko S; D'Hooghe T; Ershova A; Lispi M
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):134-148. PubMed ID: 35216907
[TBL] [Abstract][Full Text] [Related]
20. A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.
Bühler K; Naether OG; Bilger W
Reprod Biol Endocrinol; 2014 Jan; 12():6. PubMed ID: 24423045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
